Vifor Pharma

Photo

CSL Takes Vifor Pharma for $11.7 Billion

After days of speculation, it’s now official. Australian biopharmaceuticals manufacturer CSL has grabbed for and won the hand of Swiss Vifor Pharma. The boards of both companies have unanimously approved the $11.7 billion public tender offer, which looks certain to be accepted by Vifor’s shareholders. Its largest, Patinex, with 23%, has already agreed to tender.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.